Improving the treatment efficacy of chronic dermatoses

Yu.E. Rusak, A.V. Gorshkova, E.N. Efanova

Surgut State University, Surgut

Aim: to increase the treatment efficacy of chronic dermatoses by including meldonium in complex therapy.

Patients and Methods: a prospective study was conducted, which included 40 patients: 24 of them women with atopic dermatitis (n=14), eczema (n=14) and psoriasis (n=12). The median age was 51.3 years. Concomitant pathology was observed in 20 patients, while the other
20 patients had a comorbid condition. Depending on the indicated treatment, the patients were divided into 2 groups of 20 subjects. Group 1 with comorbid diseases received standard treatment using antihistamines, external glucocorticosteroids for 4 weeks. Group 2 with concomitant pathology received similar treatment according to the standard regimen with meldonium addition at a dose of 500 mg/day for 4 weeks. The incidence of relapses, the duration of remission periods, the area of cutaneous lesions, and the values of the SpO₂ index were evaluated. The patients were followed up for 12 months.

Results: initially, all patients were characterized by the predominance of parasympathetic nervous system regulation, which was manifested by severe itching, insomnia and decreased work ability. Treatment result with the inclusion of meldonium was a decrease in the cutaneous lesions area during the next exacerbation, an increase in the duration of the relapse-free period, a reduction in the exacerbation period
to 14 days, and an increase in blood oxygen saturation level (p<0.05) versus patients who received only standard therapy.

Conclusion: meldonium inclusion in the complex therapy of chronic dermatoses in the setting of comorbid and concomitant pathology increases the therapy efficacy, improves sleep and increases work ability.

Keywords: chronic dermatoses, atopic dermatitis, eczema, psoriasis, patients, meldonium, comorbid condition.

For citation: Rusak Yu.E., Gorshkova A.V., Efanova E.N. Improving the treatment efficacy of chronic dermatoses. RMJ. 2021;4:78–80.